CA2268450C - Neurotrophin antagonist compositions - Google Patents

Neurotrophin antagonist compositions Download PDF

Info

Publication number
CA2268450C
CA2268450C CA002268450A CA2268450A CA2268450C CA 2268450 C CA2268450 C CA 2268450C CA 002268450 A CA002268450 A CA 002268450A CA 2268450 A CA2268450 A CA 2268450A CA 2268450 C CA2268450 C CA 2268450C
Authority
CA
Canada
Prior art keywords
isoquinoline
dioxo
tetrahydrobenzo
nitro
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002268450A
Other languages
English (en)
French (fr)
Other versions
CA2268450A1 (en
Inventor
Ashok Tehim
Xiannong Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Painceptor Pharma Corp
Original Assignee
NPS Allelix Corp Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9621902.7A external-priority patent/GB9621902D0/en
Priority claimed from GBGB9710904.5A external-priority patent/GB9710904D0/en
Application filed by NPS Allelix Corp Canada filed Critical NPS Allelix Corp Canada
Publication of CA2268450A1 publication Critical patent/CA2268450A1/en
Application granted granted Critical
Publication of CA2268450C publication Critical patent/CA2268450C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002268450A 1996-10-21 1997-10-20 Neurotrophin antagonist compositions Expired - Fee Related CA2268450C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9621902.7A GB9621902D0 (en) 1996-10-21 1996-10-21 Neurotrophin antagonist compositions
GB9621902.7 1997-05-27
GB9710904.5 1997-05-27
GBGB9710904.5A GB9710904D0 (en) 1997-05-27 1997-05-27 Neurotropin antagonist compositions
PCT/CA1997/000779 WO1998017278A1 (en) 1996-10-21 1997-10-20 Neurotrophin antagonist compositions

Publications (2)

Publication Number Publication Date
CA2268450A1 CA2268450A1 (en) 1998-04-30
CA2268450C true CA2268450C (en) 2008-08-05

Family

ID=26310264

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002268450A Expired - Fee Related CA2268450C (en) 1996-10-21 1997-10-20 Neurotrophin antagonist compositions

Country Status (14)

Country Link
US (4) US20020169182A1 (https=)
EP (1) EP0930883B1 (https=)
JP (1) JP2001503397A (https=)
KR (1) KR20000052691A (https=)
AT (1) ATE315397T1 (https=)
AU (1) AU728523C (https=)
BR (1) BR9712424A (https=)
CA (1) CA2268450C (https=)
DE (1) DE69735090T2 (https=)
DK (1) DK0930883T3 (https=)
ES (1) ES2257768T3 (https=)
IL (1) IL129475A0 (https=)
NZ (1) NZ335291A (https=)
WO (1) WO1998017278A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0930883B1 (en) 1996-10-21 2006-01-11 Allelix Biopharmaceuticals Inc. Neurotrophin antagonists for the treatment of epilepsy, alzheimer's disease and pain
MXPA01005228A (es) * 1998-11-25 2002-06-21 Merck Patent Gmbh Benzo(de)isoquinolin-1, 3-dionas substituidas.
AU760136B2 (en) * 1998-11-25 2003-05-08 Merck Patent Gmbh Substituted benzo(DE)isoquinoline-1,3-diones
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
US6492380B1 (en) * 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP2191846A1 (en) 2003-02-19 2010-06-02 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
JP5301152B2 (ja) 2004-04-07 2013-09-25 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
GB0419850D0 (en) * 2004-09-07 2004-10-13 Angeletti P Ist Richerche Bio Therapeutic agents
BRPI0615930A2 (pt) * 2005-09-15 2016-08-23 Painceptor Pharma Corp métodos de modular a interação de uma neurotrofina e um receptor de neurotrofina, de tratar dor em um indivíduo, de tratar distúrbio inflamatório em um indivíduo, de tratar um distúrbio neurológico em um indivíduo, e de tratar uma doença ou distúrbio associado aos sistemas geniturinário e/ou gastrointestinal de um indivíduo, e, composto
WO2009039635A1 (en) * 2007-09-24 2009-04-02 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
JP2021517461A (ja) 2018-03-12 2021-07-26 ゾエティス・サービシーズ・エルエルシー 抗ｎｇｆ抗体およびその方法
CA3190144A1 (en) * 2020-07-24 2022-01-27 Jawaharlal Nehru Centre For Advanced Scientific Research Naphthalene monoimide compounds and methods thereof
US20230348608A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score
AU2024238259A1 (en) 2023-03-17 2025-08-21 Regeneron Pharmaceuticals, Inc. Proteomic risk score for osteoarthritis (oa)
WO2026054762A1 (en) 2024-09-05 2026-03-12 Regeneron Pharmaceuticals, Inc. Proteomic risk score for adjudicated arthropathy (aa)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US525841A (en) * 1894-09-11 Baling-press
US627129A (en) * 1899-06-20 Collar-edge-ironing machine
US3821383A (en) * 1972-07-10 1974-06-28 Ayerst Mckenna & Harrison Compositions for and a method of treating diabetic complications
US4006238A (en) * 1975-08-28 1977-02-01 E. R. Squibb & Sons, Inc. Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents
ES459497A1 (es) * 1977-06-04 1978-04-16 Made Labor Sa Un metodo para la preparacion industrial de naftalimidas y sus derivados.
US4254109A (en) * 1979-11-08 1981-03-03 Ayerst, Mckenna & Harrison Inc. 1H-Benz[de]isoquinoline-2(3H)-acetic acid derivatives
RU2051677C1 (ru) * 1982-02-10 1996-01-10 Украинский научно-исследовательский институт эндокринологии и обмена веществ Средство для профилактики и лечения диабетических осложнений, ангиопатий, нейропатий, катаракты
US5183821A (en) * 1983-09-19 1993-02-02 Laboratories Knoll, S.A. Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors
IT1214618B (it) * 1985-06-27 1990-01-18 I P A International Pharmaceut Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche.
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
DE3707651A1 (de) * 1987-03-10 1988-09-22 Knoll Ag Bis-naphthalimide, ihre herstellung und verwendung
DE3707652A1 (de) * 1987-03-10 1988-09-22 Knoll Ag Verwendung von benzo(de)isochinolin-1,3-dionen zur herstellung von arzneimitteln
US5420137A (en) * 1989-07-11 1995-05-30 Knoll Ag Amonafide salts
US5356906A (en) * 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
CA2030129A1 (en) * 1989-11-29 1991-05-30 Thomas Saupe 1,8-napthalenedicarboximides as antidotes
US5342942A (en) * 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
DE4232739A1 (de) * 1992-09-30 1994-03-31 Knoll Ag Neue asymmetrisch substituierte bis-Naphthalimide
IL110460A (en) * 1993-08-18 2001-01-11 Basf Ag Bis-naphthalimides, their preparation and pharmaceutical compositions containing them
US6291247B1 (en) * 1994-05-11 2001-09-18 Queen's University At Kingston Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
GB9616105D0 (en) * 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
EP0930883B1 (en) 1996-10-21 2006-01-11 Allelix Biopharmaceuticals Inc. Neurotrophin antagonists for the treatment of epilepsy, alzheimer's disease and pain
CA2319680C (en) 1997-02-07 2010-04-20 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1998052919A1 (en) 1997-05-21 1998-11-26 Japan Tobacco Inc. Phthalimide derivatives and pharmaceutical containing said derivatives
WO2000000472A1 (en) 1998-06-30 2000-01-06 Du Pont Pharmaceuticals Company 5-ht7 receptor antagonists
EP1020446B1 (en) * 1998-07-03 2006-03-15 Taiho Pharmaceutical Co., Ltd. Naphthalimidobenzamide derivatives
US6492380B1 (en) * 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor

Also Published As

Publication number Publication date
US7291629B2 (en) 2007-11-06
IL129475A0 (en) 2000-02-29
AU4696897A (en) 1998-05-15
AU728523B2 (en) 2001-01-11
ES2257768T3 (es) 2006-08-01
WO1998017278A1 (en) 1998-04-30
ATE315397T1 (de) 2006-02-15
DK0930883T3 (da) 2006-05-22
US20080287484A1 (en) 2008-11-20
DE69735090D1 (de) 2006-04-06
US20050250807A1 (en) 2005-11-10
DE69735090T2 (de) 2006-09-14
EP0930883B1 (en) 2006-01-11
CA2268450A1 (en) 1998-04-30
AU728523C (en) 2001-08-09
BR9712424A (pt) 2001-11-20
KR20000052691A (ko) 2000-08-25
US20020169182A1 (en) 2002-11-14
EP0930883A1 (en) 1999-07-28
JP2001503397A (ja) 2001-03-13
US20090215815A1 (en) 2009-08-27
NZ335291A (en) 2001-02-23

Similar Documents

Publication Publication Date Title
CA2268450C (en) Neurotrophin antagonist compositions
US6492380B1 (en) Method of inhibiting neurotrophin-receptor binding
US6468990B1 (en) Method of inhibiting binding of nerve growth factor to p75 NTR receptor
DE2623567C2 (de) Thienopyridinderivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittelzubereitungen
WO2009039635A1 (en) Methods of modulating neurotrophin-mediated activity
JP2003501418A (ja) 細胞死を阻害するための組成物および方法
DE69811492T2 (de) Benzonaphthyridine
US5922875A (en) Aromatic acid diamides with antigastrin activity, a method for their preparation and their pharmaceutical use
MXPA99003637A (es) Composiciones antagonistas de las neurotrofinas
US6057334A (en) Benzo[g]quinoline derivatives
US20040072862A1 (en) Compositions for treating ischemia-related neuronal damage
EP1057830A1 (en) Heterocycle-fused benzothiazine derivatives
JP2002529470A (ja) 縮合ピリダジノン化合物
AU2005201951C1 (en) Method of inhibiting neurotrophin-receptor binding

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed